<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">26129</article-id><article-id pub-id-type="doi">10.7554/eLife.26129</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-82929"><name><surname>Fan</surname><given-names>Yichao</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82930"><name><surname>Yue</surname><given-names>Jiao</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-82931"><name><surname>Xiao</surname><given-names>Mengtao</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-82932"><name><surname>Han-Zhang</surname><given-names>Han</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-92970"><name><surname>Wang</surname><given-names>Yao Vickie</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-92971"><name><surname>Ma</surname><given-names>Chun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-92972"><name><surname>Deng</surname><given-names>Zhilin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82933"><name><surname>Li</surname><given-names>Yingxiang</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0835-9280</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82934"><name><surname>Yu</surname><given-names>Yanyan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-14057"><name><surname>Wang</surname><given-names>Xinghao</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-82936"><name><surname>Niu</surname><given-names>Shen</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-82937"><name><surname>Hua</surname><given-names>Youjia</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-54522"><name><surname>Weng</surname><given-names>Zhiping</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-14066"><name><surname>Atadja</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-14068"><name><surname>Li</surname><given-names>En</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-81756"><name><surname>Xiang</surname><given-names>Bin</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6973-100X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Epigenetic Discovery</institution>, <institution>Novartis Institute for BioMedical Research</institution>, <addr-line><named-content content-type="city">Shanghai</named-content></addr-line>, <country>China</country></aff><aff id="aff2"><institution content-type="dept">Epigenetic Discovery</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Shanghai</named-content></addr-line>, <country>China</country></aff><aff id="aff3"><institution content-type="dept">Department of Bioinformatics</institution>, <institution>Tongji University</institution>, <addr-line><named-content content-type="city">Shanghai</named-content></addr-line>, <country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-14864"><name><surname>Davidson</surname><given-names>Irwin</given-names></name><role>Reviewing editor</role><aff><institution>Institut de Génétique et de Biologie Moléculaire et Cellulaire</institution>, <country>France</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>bin.xiang@novartis.com</email> (BX);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>02</day><month>08</month><year>2017</year></pub-date><volume>6</volume><elocation-id>e26129</elocation-id><history><date date-type="received"><day>17</day><month>02</month><year>2017</year></date><date date-type="accepted"><day>01</day><month>08</month><year>2017</year></date></history><permissions><copyright-statement>© 2017, Fan et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Fan et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-26129-v2.pdf"/><abstract><p>Tumor suppressor p53 prevents cell transformation by inducing apoptosis and other responses. Homozygous <italic>TP53 </italic>deletion occurs in various types of human cancers for which no therapeutic strategies have yet been reported. Based on TCGA database analysis, <italic>TP53</italic> homozygous deletion locus mostly exhibits co-deletion of the neighboring gene <italic>FXR2,</italic> which belongs to the Fragile X gene family. Here, we demonstrate that inhibition of the remaining family member FXR1 selectively blocks cell proliferation in cancer cells containing homozygous deletion of both <italic>TP53</italic> and <italic>FXR2 </italic>in a collateral lethality manner. Mechanistically, in addition to its RNA-binding function, FXR1 recruits transcription factor STAT1 or STAT3 to gene promoters at the chromatin interface and regulates transcription thus, at least partially, mediating cell proliferation. Our study anticipates that inhibition of FXR1 is a potential therapeutic approach to targeting human cancers harboring <italic>TP53</italic> homozygous deletion.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source><award-id>Research</award-id><principal-award-recipient><name><surname>Xiang</surname><given-names>Bin</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004336</institution-id><institution>Novartis</institution></institution-wrap></funding-source><award-id>Postdoc program</award-id><principal-award-recipient><name><surname>Fan</surname><given-names>Yichao</given-names></name></principal-award-recipient></award-group><funding-statement>The authors declare that there was no funding for this work.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Jiao Yue, Jiao Yue is an employee for Novartis, Inc., where part of the study was conducted..</p></fn><fn fn-type="conflict" id="conf3"><p>Mengtao Xiao, Mengtao Xiao is an employee for Novartis, Inc., where part of the study was conducted..</p></fn><fn fn-type="conflict" id="conf4"><p>Han Han-Zhang, Han Han-Zhang is an employee for Novartis, Inc., where part of the study was conducted..</p></fn><fn fn-type="conflict" id="conf5"><p>Yanyan Yu, Yanyan Yu is an employee for Novartis, Inc., where part of the study was conducted..</p></fn><fn fn-type="conflict" id="conf6"><p>Shen Niu, Shen Niu is an employee for Novartis, Inc., where part of the study was conducted..</p></fn><fn fn-type="conflict" id="conf7"><p>Youjia Hua, Youjia Hua is an employee for Novartis, Inc., where part of the study was conducted..</p></fn><fn fn-type="conflict" id="conf8"><p>Peter Atadja, Peter Atadja is an employee for Novartis, Inc., where part of the study was conducted..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All the procedures related to animal handling, care and the treatment in the study were performed according to the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of WuXi AppTec following the guidance of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). The approved protocol number is R20150728-Mouse and Rat. The animals were daily checked for any effects of tumor growth and treatments on normal behavior such as mobility, food and water consumption, body weight gain/loss, eye/hair matting and any other abnormal effects. Death and observed clinical signs were recorded.</p></fn></fn-group></sec><sec sec-type="supplementary-material"><supplementary-material><ext-link xlink:href="elife-26129-supp-v2.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>